Midway through 2026, I have some cautiously positive news to share. The MedTech labor market is not back to the hyperactive environment we saw in 2021 and early 2022, but it continues to show signs of selective improvement. The strongest companies are still hiring. Candidates with the right industry skill sets are still getting attention. And strategic activity across the sector remains active.
Personally, I have continued to see a steady flow of roles across Medical Technologies. Since Labor Day 2024, I have consistently had openings across Engineering, Quality, Regulatory, Market Access, Sales, and Marketing. The market is not broad-based, but it is healthier than it was during the slower 2023 and early 2024 environment.
I am also seeing more candidate activity. Many of the candidates I’m presenting to clients are also speaking with other companies. In some cases, I am seeing competing processes and competing offers. That does not mean every MedTech professional has an easy market, but it does suggest that companies are moving when they find people with the right skill set.
The underlying mechanics of the labor market remain tied to financial activity. Funding is more selective than it was during the peak years, but M&A activity has been strong. That matters because strategic acquisitions, portfolio reshaping, manufacturing scale-up, integration work, and commercial expansion all create hiring needs.
MedTech Funding Trends in 2026
We now have a clearer picture of MedTech venture funding through the first half of 2026. According to the updated J.P. Morgan / DealForma Q2 2026 MedTech report, MedTech venture funding totaled approximately $5.0 billion across 164 rounds in the first half of 2026. Q1 and Q2 were very similar, with each quarter coming in around $2.5 billion.
That tells us funding has stabilized quarter to quarter, but it remains below the stronger levels we saw in 2024 and 2025. This is not a broad-based funding boom. It is a more selective environment where capital is still available, but flowing toward companies with clearer clinical, regulatory, reimbursement, commercial, or strategic value.
Data points to consider:
- First half of 2024: approximately $40.3 billion across 114 transactions
- First half of 2025: approximately $11.3 billion across 100 transactions
- Q1 2025: approximately $9.2 billion across 57 M&A transactions
- Q2 2025: approximately $2.1 billion across 43 transactions
- First half of 2026: Approximately $5.0 billion in MedTech venture funding across 164 rounds.
- Q1 2026: Approximately $2.5 billion in MedTech venture funding across 79 rounds.
- Q2 2026: Approximately $2.5 billion in MedTech venture funding, roughly in line with Q1.
- 2026 full-year run rate: Approximately $10.0 billion, which would be below full-year 2025 and reflects a more selective capital environment.
Another important detail is where the money is going. In the first half of 2026, later-stage companies captured most of the capital. Series B and later rounds accounted for approximately $4.1 billion across 102 deals, while Seed and Series A accounted for roughly $940 million across 62 deals. The report also noted 39 rounds above $50 million, including nine rounds above $100 million.
This matters for the labor market. A selective funding environment does not create the same broad hiring lift as a speculative funding environment. However, when capital is concentrated in stronger companies, those companies still hire. They tend to hire more carefully, but they still need experienced people in product development, clinical, regulatory, quality, reimbursement, commercial strategy, sales, marketing, and operations.
It also means hiring has become more precise. Companies are narrowing requirements and looking for people who have solved specific problems before: a particular product category, regulatory pathway, customer call point, commercialization stage, manufacturing challenge, or quality system need.
How Are MedTech Acquisitions Looking?
M&A is the stronger story so far in 2026.
In Q1 2026, MedTech M&A totaled approximately $26.6 billion across 37 deals. For the first half of 2026, PwC reported approximately $36.5 billion in MedTech M&A deal value. That puts 2026 on pace for another strong year.
Current M&A data points to consider:
- Q1 2026: Approximately $26.6 billion in MedTech M&A across 37 deals.
- First half of 2026: Approximately $36.5 billion in MedTech M&A deal value.
- Q1 2025: Approximately $8.1 billion in MedTech M&A.
- Q2 2025: Approximately $2.1 billion in MedTech M&A.
- First half of 2024: Approximately $40.3 billion in MedTech M&A across 114 acquisitions.
This tells me something important. Buyers are still being selective, but they are willing to make large moves when an asset fits their strategic priorities. This is not random dealmaking. It is focused dealmaking. Companies are looking for differentiated technology, commercial traction, AI-enabled workflows, robotics, connected care, diagnostics, cardiovascular platforms, and assets that strengthen core growth areas.
We are also seeing continued portfolio reshaping. Larger MedTech companies are refining where they want to compete. That often creates direct and indirect hiring demand: integration roles, quality and regulatory leadership, manufacturing transfer, product management, commercial leadership, reimbursement, market development, and sales expansion.
What This Means for the MedTech Labor Market
The message for the rest of 2026 is not that every company is hiring aggressively. That would overstate the market.
The better read is this: the MedTech labor market is selective but active.
Funding is stable quarter to quarter in 2026, but it is still down compared with the first half of 2025 and the first half of 2024. That limits broad startup hiring. However, the M&A environment is strong, and strategic buyers continue to invest in companies and technologies that fit long-term growth priorities.
For candidates, this means the best opportunities are likely to be with companies that have real capital, clinical or commercial traction, and a clear reason to hire. Companies are still cautious, but they will compete for people who bring directly relevant experience.
For hiring leaders, this means the market is not as easy as it may appear from the outside. Strong MedTech candidates are often in multiple conversations, and the best candidates may not be actively applying.
All of this creates a labor market where precision matters more than volume. This is where using an experienced recruiter can make a real difference. As hiring becomes narrower and more specialized, companies need more than applicant flow. They need market intelligence, targeted outreach, compensation feedback, candidate calibration, and a clear understanding of how their opportunity compares to others in the market.
A specialized MedTech recruiter can help identify candidates who are not visible through job postings, screen for directly relevant industry experience, and separate “close enough” resumes from people who truly match the stage, product, function, and regulatory environment. That precision matters more in 2026 because companies have less room for hiring mistakes and candidates with the right skill sets often have multiple options.
Capitalize on a Selectively Strong MedTech Market
If you need help navigating this selectively strong MedTech market, our team is here to support your next chapter. Contact us today.
The opportunity is not everywhere, but it is real. In a market like this, timing, access, and specialization matter. Whether you are exploring a new role or trying to find the right person to help your company move forward, working with a specialized MedTech recruiter can help you navigate the market with better information, better reach, and a more focused process.
The MedTech market is still evolving, and for the right companies and the right people, there is meaningful opportunity in the second half of 2026.
